CD274 and gastroesophageal junction adenocarcinoma: In Europe, for advanced esophagogastric adenocarcinoma, first-line therapy in Her-2-negative tumors includes (i) nivolumab in association with chemotherapy in patients with PD-L1 CPS (combined positive score) ≥ 5 [63]; (ii) pembrolizumab plus chemotherapy in PD-L1 CPS ≥ 10; (iii) doublet or triplet chemotherapy alone in PD-L1 CPS < 5 [64].